{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:15:33Z","timestamp":1780676133473,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journal-of-cardiology.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jjcc.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T09:00:12Z","timestamp":1711098012000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid"],"prefix":"10.1016","volume":"84","author":[{"given":"Siva Naga S.","family":"Yarrarapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikramaditya Samala","family":"Venkata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barath Prashanth","family":"Sivasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doantrang T.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopesh Sai","family":"Jakulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Pamulapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazhar A.","family":"Afaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Dalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2024.03.006_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ccd.29745","article-title":"Racial and ethnic disparities in coronary, vascular, structural, and congenital heart disease","volume":"98","author":"Grines","year":"2021","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0015","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11883-023-01103-4","article-title":"Highlights of cardiovascular disease prevention studies presented at the 2023 American College of Cardiology Conference","volume":"25","author":"Gupta","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-015-0552-3","article-title":"Statin intolerance: the clinician\u2019s perspective","volume":"17","author":"Stulc","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0055","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0060","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"The National Lipid Association\u2019s statin safety task force. An assessment by the statin liver safety task force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0065","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"The National Lipid Association\u2019s safety task force. An assessment by the statin cognitive safety task force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0070","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, Aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0080","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101714","article-title":"Management of patients with statin intolerance","volume":"37","author":"Martirossian","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2023.02.007","article-title":"PCSK9 inhibitor, ezetimibe, and bempedoic acid: evidence-based therapies for statin-intolerant patients","volume":"79","author":"Gunta","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0095","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0100","series-title":"Statin-associated muscle symptoms","year":"2020"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S11244","article-title":"Treating statin-intolerant patients","volume":"4","author":"Arca","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0110","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.clinthera.2006.06.004","article-title":"Rosuvastatin 5 and 10 mg\/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies","volume":"28","author":"Glueck","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ndt\/gfg048","article-title":"Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients","volume":"18","author":"Lins","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.amjcard.2006.07.093","article-title":"Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy","volume":"99","author":"Mackie","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0125","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins","volume":"101","author":"Gadarla","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0130","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1567-5688(17)30024-7","article-title":"SAMS expert working group. Practical aspects in the management of statin-associated muscle symptoms (SAMS)","volume":"26","author":"Laufs","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0145","first-page":"52","article-title":"Plant sterols\/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food","author":"Abumweis","year":"2008","journal-title":"Nutr Res"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0150","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0155","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.4065\/83.11.1294","article-title":"Is red yeast rice a suitable alternative for statins?","volume":"83","author":"Carter","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0160","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1021\/jf000338c","article-title":"Constituents of red yeast rice, a traditional Chinese food and medicine","volume":"48","author":"Ma","year":"2000","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/jama.290.4.502","article-title":"Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein","volume":"290","author":"Jenkins","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0170","doi-asserted-by":"crossref","unstructured":"Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009;153:11\u20136. Available at: doi:https:\/\/doi.org\/10.1016\/j.trsl.2008.11.002.","DOI":"10.1016\/j.trsl.2008.11.002"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0175","first-page":"483","article-title":"Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer","volume":"2","author":"Thibault","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1006481423298","article-title":"Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma","volume":"19","author":"Kim","year":"2001","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/biof.5520250116","article-title":"Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation","volume":"25","author":"Langsjoen","year":"2005","journal-title":"Biofactors"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0190","doi-asserted-by":"crossref","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0195","first-page":"3A","article-title":"Coenzyme Q10 improves myopathic pain in statin treated patients","volume":"45","author":"Kelly","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0205","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0210","doi-asserted-by":"crossref","DOI":"10.1080\/13543784.2017.1280458","article-title":"Evaluating bempedoic acid for the treatment of hyperlipidaemia","volume":"26","author":"Penson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.numecd.2021.09.023","article-title":"Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia","volume":"32","author":"Averna","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0225","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2016.10.003","article-title":"Clinical and economic consequences of statin intolerance in the United States: results from an integrated health system","volume":"11","author":"Graham","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0240","doi-asserted-by":"crossref","unstructured":"Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol 2016;225:184\u201396. Available at: doi:https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.075.","DOI":"10.1016\/j.ijcard.2016.09.075"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-016-6680-3","article-title":"Algorithms to identify statin intolerance in Medicare administrative claim data","volume":"30","author":"Colantonio","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0255","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2016.03.043","article-title":"Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy","volume":"117","author":"Ballantyne","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276898","article-title":"Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk","volume":"17","author":"Katzmann","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.08.013","article-title":"Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: a cost-effectiveness analysis","volume":"14","author":"Perera","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0290","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0295","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0300","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials","volume":"334","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2007.10.034","article-title":"The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention","volume":"51","author":"Kip","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony open-label extension study)","volume":"174","author":"Ballantyne","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0315","doi-asserted-by":"crossref","first-page":"1028355","DOI":"10.3389\/fcvm.2022.1028355","article-title":"Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome","volume":"9","author":"Biolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2012.05.019","article-title":"Statins, risk of diabetes, and implications on outcomes in the general population","volume":"60","author":"Wang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0325","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","volume":"24","author":"Leiter","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0330","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0335","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107137","article-title":"Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology","volume":"148","author":"Patti","year":"2023","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.jjcc.2024.03.006_bb0345","first-page":"1366","article-title":"ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution set Oversight Committee","volume":"80","author":"Committee","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508724000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508724000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:01:18Z","timestamp":1718226078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508724000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0914508724000455"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2024.03.006","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}